IL1B and Nephropathy: In this study, the extent of kidney damage in the non-treated CKD group, which was more than 4.5-fold higher than controls, was significantly reduced with DTBN treatment, in association with a decrease in key proinflammatory mediators (IL1, IL6, NFkB and STAT3).